We found a similar proportion of FGF14 expansions in both MSA-C and MSA-P, highlighting the importance of genetic testing in both these presentations when a clinical suspicion arises, irrespective of the predominant MSA clinical subtype. Here, FGF14 is linked to multiple system atrophy.